ImmunoGen Inc (IMGN)

[skitahoe]

Doug, IMGN is far from BK, in fact if IMGN stopped all development income would simply keep growing as Kadcyla sales grow to replace Herceptin, and eventually expand on it. $5 to $10 billion in sales in a few years is very possible as trial date demonstrates its viability in many applications.

Of course other drugs are what will really explode IMGN's price, good data's routinely coming in, but trials take time and cost money, so investors are frustrated by slow rate of progress. What's important is they are progressing.

Gary